3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
18
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Rituximab
16
zanubrutinib
12
ibrutinib
9
venetoclax
8
Cyclophosphamide
8
pirtobrutinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Sirolimus
5
Mycophenolic Acid
5
Bendamustine Hydrochloride
5
acalabrutinib
4
Peripheral Blood Stem Cell Transplantation
4
Dexamethasone
4
ixazomib
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Cyclosporine
3
Bortezomib
3
Biopsy
3
fludarabine
2
carfilzomib
2
Tacrolimus
2
Prednisone
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
Sunitinib
×
1 year
×
Clear all
No trials found.